Fibromyalgia
Chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive symptoms. Cannabis has limited evidence for symptomatic improvement in fibromyalgia patients; pain and sleep outcomes are most commonly reported.
- 16 states
- QUALIFYING IN
- Limited
- EVIDENCE
- M79.7
- ICD-10
Reviewed by Laura H. Meyer
Qualifying states
What it is
Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, persistent fatigue, sleep disturbance, and cognitive symptoms ("fibro fog"). The pathophysiology involves central sensitization (abnormal pain processing in the brain and spinal cord) rather than peripheral tissue injury. Patients commonly experience tender points across multiple body regions.
Standard treatment includes exercise therapy, cognitive-behavioral therapy, and pharmacologic agents (duloxetine, milnacipran, pregabalin).
Cannabis and cannabis-derived therapies
Evidence for cannabis in fibromyalgia is limited. Several small randomized trials and observational studies of nabilone and cannabis-derived products have reported modest improvements in pain, sleep, and quality-of-life measures. Heterogeneity in study design, dosing, and outcome measures limits the strength of pooled conclusions.
Fibromyalgia is a qualifying condition under medical cannabis programs in states with broad pain qualifiers (e.g. New York, New Mexico, Illinois) or specifically enumerated chronic pain syndromes (Arkansas, Hawaii, Pennsylvania). Patients should integrate cannabis use into a broader fibromyalgia management plan rather than substitute it for evidence-based pharmacologic and behavioral therapies.
Frequently asked questions
What does the evidence say about cannabis for fibromyalgia?
Limited. The 2017 NASEM report did not identify fibromyalgia as a condition with substantial or conclusive evidence for cannabis. Small clinical trials and observational studies suggest possible improvement in pain and sleep, but trial sizes are modest and outcomes inconsistent. NIAMS does not endorse cannabis as a fibromyalgia therapy.
Is any cannabis-derived product FDA-approved for fibromyalgia?
No. No cannabis or cannabinoid product is FDA-approved for fibromyalgia. FDA-approved medications for fibromyalgia include duloxetine, milnacipran, and pregabalin. Cognitive behavioral therapy and graded aerobic exercise have the strongest non-pharmacologic evidence base.
Which forms and doses are typically used by fibromyalgia patients?
Most patient-reported use combines low-to-moderate THC products with CBD, often via oils, tinctures, or edibles for daytime symptom management and inhaled forms for breakthrough pain. Sedation, cognitive effects, and tolerance are common concerns. Cannabis interacts with antidepressants and sleep medications; disclosure to the prescribing clinician is important.
Why is fibromyalgia a qualifying condition in some states but not others?
State inclusion varies because the evidence base is limited and fibromyalgia overlaps clinically with chronic-pain and central-sensitization syndromes that are already qualifying. States such as Arkansas, Illinois, and New Mexico enumerate fibromyalgia specifically; many other states cover the same patient population under a "chronic pain" qualifier without naming fibromyalgia.
Sources
- NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases: Fibromyalgiaaccessed May 15, 2026
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 15, 2026